[1]
Charles PG, Grayson ML. The dearth of new antibiotic development: Why we should be worried and what we can do about it. Med J Aust 2004; 181: 549-53.
[2]
Levy SB. Antibiotic resistance-the problem intensifies. Adv Drug Deliv Rev 2005; 57: 1446-50.
[3]
Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med 2002; 252: 91-106.
[4]
Odonkor ST, Addo KK. Bacteria resistance to antibiotics: Recent trends and challenges. Int J Biol Med Res 2011; 2: 1204-10.
[5]
Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39: 283-94.
[6]
Gallucci MN, Carezzano ME, Oliva MM, et al. In vitro activity of natural phenolic compounds against fluconazole-resistant Candida species: A quantitative structure-activity relationship analysis. J Appl Microbiol 2014; 116: 795-804.
[7]
Brickner SJ, Hutchinson DK, Barbachyn MR, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J Med Chem 1996; 39: 673-9.
[8]
a) Johnson AP, Tysall L, Stockdale MW, et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faeciumisolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002; 21: 751-4.; b) Auckland C, Teare L, Cooke F, et al. Linezolid-resistant enterococci: Report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002; 50: 743-6.
[9]
Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid
resistance in a clinical isolate of Staphylococcus
aureus. Lancet 2001; 358: 207-31.; b) Wilson p , Andrews JA, , Charlesworth R, , et al. Linezolid resistance
in clinical isolates of Staphylococcus aureus. J
Antimicrob Chemother 2003; 51: 186-8.
[10]
Krátký M, Volková M, Novotná E, et al. Synthesis and biological activity of new salicylanilide N,N-disubstituted carbamates and thiocarbamates. Bioorg Med Chem 2014; 22: 4073-82.
[11]
Ryder NS, Frank I, Dupont MC. Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agentstolnaftate and tolciclate. Antimicrob Agents Chemother 1986; 29: 858-60.
[12]
Mukherjee PK, Leidich SD, Isham N, et al. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother 2003; 47: 82-6.
[13]
Krátký M, Vinšová J. Salicylanilide N-monosubstituted carbamates: Synthesis and in vitro antimicrobial activity. Bioorg Med Chem 2016; 24: 1322-30.
[14]
Jang S-Y, Ha YH, Ko SW, et al. Synthesis and antibacterial activity of arylpiperazinyloxazolidinones with diversification of the N-substituents. Bioorg Med Chem Lett 2004; 14: 3881-3.
[15]
Thayer AM. Rapid screening and optimization of enzymatic activity, along with available, easy-to-use enzymes, are making biocatalysis a handy tool for chiral synthesis. Chem Eng News 2006; 84: 15-25.
[16]
Kirk KL. Fluorination in medicinal chemistry: Methods, strategies, and recent developments. Org Process Res Dev 2008; 12: 305-21.
[17]
Hagmann WK. The many roles for fluorine in medicinal chemistry. J Med Chem 2008; 51: 4359-69.
[18]
Prakash GKS, Chacko S. Novel nucleophilic and electrophilic fluoroalkylation methods. Curr Opin Drug Discov Devel 2008; 11: 793-802.
[19]
Furuya T, Kuttruff CA, Ritte T. Carbon–fluorine bond formation. Curr Opin Drug Discov Devel 2008; 11: 803-19.
[20]
Wu J, Cao S, Liu N, et al. A general strategy for construction of a difluoromethyl compound library and its application in synthesis of pseudopeptides bearing a terminal difluoromethyl group. Org Biomol Chem 2010; 8: 2386-91.
[21]
Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem 2011; 54: 2529-91.
[22]
Rewcastle GW, Gamage SA, Flanagan JU, Frederic R, Denny WA. Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). J Med Chem 2011; 54: 7105-26.
[23]
Chniti I, Sanhoury MAK, Chehidi I. O-perfluoroalkylthiocarbamates: Synthesis and perfluoroalkyl effects on the barrier to N-CS rotation. J Fluor Chem 2013; 156: 101-5.
[24]
Chniti I, Sanhoury MAK, Merlet D, Chehidi I. Synthesis and conformational study of new S-polyfluoroalkyldithiocarbamates. J Fluor Chem 2014; 168: 223-9.
[25]
Belkacem-Hanfi N, Fhoula I, Semmar N, et al. Lactic acid bacteria against post-harvest moulds and ochratoxin A isolated from stored wheat. Biol Control 2014; 76: 52-9.
[26]
Chahad OB, Bour ME, Calo-Mata P, Boudabous A, Barros-Velazquez J. Discovery of novel biopreservation agents with inhibitory effects on growth of food-borne pathogens and their application to seafood products. Res Microbiol 2012; 163: 44-54.
[27]
Klibi N, Ben Amor I, Rahmouni M, et al. Diversity of species and antibiotic resistance among fecal enterococci from wild birds in Tunisia. Detection of vanA-containing Enterococcus faecium isolates. Eur J Wildl Res 2015; 61: 319-23.
[28]
Tayh G, Ben Sallem R, Ben Yahia H, et al. First report of extended-spectrum β-lactamases among clinical isolates of Escherichia coli in Gaza Strip, Palestine. J Glob Antimicrob Resist 2016; 6: 17-21.
[29]
Reference method for broth dilution antifungal susceptibility
testing of yeasts, approved standard. 3rd
ed. Wayne, PA: Clinical laboratory standards institute
(CLSI) 2008.
[30]
Methods for dilution antimicrobial susceptibility tests
for bacteria that grow aerobically. Approved standard
M7-A4. Wayne, PA: National committee for clinical
laboratory standards 2000.
[31]
Zhang L, Jiao B, Yang X, Liu L, Ma S. Synthesis and antibacterial activity of new 4″-O-carbamates of 11,12-cyclic carbonate erythromycin A 6,9-imino ether. J Antibiot 2011; 64: 243-7.
[32]
Krátky M, Bosze S, Baranyai Z, et al. Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates. Bioorg Med Chem 2015; 23: 868-75.
